BioSpace News Archive

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of a manuscript in a leading journal in the organ transplant space, Transplantation, validating the performance of a novel two-threshold algorithm for its Prospera™ test for the assessment of transplant rejection.

Exicure, Inc. announced that, following the implementation of a one-for-thirty reverse stock split at 5:00 p.m. EDT today, the Company’s common stock will begin trading on a split-adjusted basis on Nasdaq effective with the open of business tomorrow, Thursday, June 30, 2022.

Regard (formerly known as HealthTensor), a software company developing an artificial intelligence (AI) co-pilot for physicians to help diagnose medical conditions, today announced it has raised $15.3 million in Series A funding.

Hoth Therapeutics, Inc. announced that the Company received confirmation from the Listing Qualification Department of The NASDAQ Capital Market notifying the Company that Nasdaq has granted the Company an additional 180-day compliance period, or until December 26, 2022, to regain compliance with Nasdaq’s minimum $1.00 closing bid price per share requirement.

On Friday, U.S. Senators Chris Van Hollen (D-MD) and Ben Ray Lujan (D-NM), and U.S. Reps. Don Beyer (D-VA), and Kim Schrier (D-WA) introduced legislation, the Improving Diagnosis in Medicine Act of 2022 (H.R.8172/S.4468) to focus federal health agencies on tackling the root causes of diagnostic error.

Adagene Inc. announced that its board of directors has authorized a share repurchase program under which, Adagene may repurchase up to US$10 million of its ordinary shares in the form of American depositary shares, subject to the relevant rules under the Securities Exchange Act of 1934, as amended, and the Company’s insider trading policy.

Apexigen, Inc., a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, announced the appointment of Meenu Karson as a member and Chair of Apexigen’s Board of Directors, succeeding Kenneth Fong, Ph.D., as Chair.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain today congratulates partner Neurona Therapeutics on dosing the first patient in their Phase 1/2 clinical trial of its lead program NRTX-1001, in a first-in-human epilepsy study.

Teva Pharmaceutical Industries Ltd. announced that it will issue a press release on its second quarter 2022 financial results on Wednesday, July 27, 2022 at 7:00 a.m. ET.

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new vaccine supply agreement with the U.S. government to support the continued fight against COVID-19.